We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 91 for:    ALCANTARA study
Previous Study | Return to List | Next Study

Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02000427
First Posted: December 4, 2013
Last Update Posted: August 9, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Amgen
  Purpose
The primary objective is to evaluate the rate of complete remission/complete remission with partial hematological recovery (CRh*) in adults with relapsed/refractory Philadelphia chromosome positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL) who receive blinatumomab.

Condition Intervention Phase
Relapsed/Refractory Philadelphia Positive B-precursor ALL Drug: Blinatumomab Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Antibody Blinatumomab in Adult Subjects With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study)

Resource links provided by NLM:


Further study details as provided by Amgen:

Primary Outcome Measures:
  • Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles [ Time Frame: Approximately 12 weeks, as of the data cut-off date of 20 May 2015 ]

    Participants were evaluated for efficacy at the end of each treatment cycle via a central bone marrow aspiration and local peripheral blood counts.

    Complete remission was defined as meeting all 3 of the following criteria:

    • less than or equal to 5% blasts in the bone marrow;
    • no evidence of disease
    • full recovery of peripheral blood counts: platelets > 100,000/μl, and absolute neutrophil count (ANC) > 1000/μl.

    Complete remission with partial hematological recovery (CRh*) was defined as meeting all 3 of the following criteria:

    • less than or equal to 5% blasts in the bone marrow
    • no evidence of disease
    • partial recovery of peripheral blood counts: platelets > 50,000/μl, and ANC > 500/μl.

    Participants without a post-baseline disease assessment were considered non-responders.



Secondary Outcome Measures:
  • Percentage of Participants With Minimal Residual Disease (MRD) Remission During the First 2 Cycles of Treatment [ Time Frame: Approximately 12 weeks ]

    Bone marrow samples were evaluated for MRD remission by a central laboratory using bcr-abl fusion gene reverse transcription polymerase chain reaction (RT-PCR).

    An MRD response was defined as MRD < 10^-4 measured by PCR. Participants with no post-baseline MRD assessment were considered non-responders.


  • Duration of CR or CRh* Response [ Time Frame: Up to the data cut-off date of 20 May 2015; median observation time was 7.0 months ]
    Duration of response was measured for participants in remission (CR/CRh*), and was measured from the time the participant first achieved remission until first documented relapse or death from disease progression. Participants without a documented relapse (hematological or extramedullary) and who did not die were censored at the time of the last bone marrow assessment or the last survival follow-up visit to confirm remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their date of death.

  • Percentage of Participants With Complete Remission (CR) During the First Two Treatment Cycles [ Time Frame: Approximately 12 weeks, as of the data cut-off date of 20 May 2015 ]

    Participants were evaluated for efficacy at the end of each treatment cycle via a central bone marrow aspiration and local peripheral blood counts.

    Complete remission was defined as meeting all 3 of the following criteria:

    • less than or equal to 5% blasts in the bone marrow;
    • no evidence of disease;
    • full recovery of peripheral blood counts: platelets > 100,000/μl, and absolute neutrophil count (ANC) > 1000/μl.

    Participants without a post-baseline disease assessment were considered non-responders.


  • Percentage of Participants With Complete Remission With Partial Hematological Recovery (CRh*) During the First Two Treatment Cycles [ Time Frame: Approximately 12 weeks, as of the data cut-off date of 20 May 2015 ]

    Participants were evaluated for efficacy at the end of each treatment cycle via a central bone marrow aspiration and local peripheral blood counts.

    Complete remission with partial hematological recovery (CRh*) was defined as meeting all 3 of the following criteria:

    • less than or equal to 5% blasts in the bone marrow;
    • no evidence of disease;
    • partial recovery of peripheral blood counts: platelets > 50,000/μl, and ANC > 500/μl.

    Participants without a post-baseline disease assessment were considered non-responders.


  • Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery/Complete Remission With Incomplete Hematological Recovery (CR/CRh*/CRi) During the First Two Treatment Cycles [ Time Frame: Approximately 12 weeks, as of the data cut-off date of 20 May 2015 ]

    Efficacy was evaluated via a central bone marrow aspiration and local peripheral blood counts.

    Complete remission was defined as meeting the following criteria:

    • less than or equal to 5% blasts in the bone marrow;
    • no evidence of disease;
    • full recovery of peripheral blood counts: platelets > 100,000/μl, and absolute neutrophil count (ANC) > 1000/μl.

    Complete remission with partial hematological recovery was defined as meeting the following criteria:

    • less than or equal to 5% blasts in the bone marrow;
    • no evidence of disease;
    • partial recovery of peripheral blood counts: platelets > 50,000/μl, and ANC > 500/μl.

    Complete remission with incomplete hematologic recovery was defined as meeting all of the following criteria:

    • less than or equal to 5% blasts in the bone marrow;
    • no evidence of disease;
    • incomplete recovery of peripheral blood counts: platelets > 100,000/μl or ANC > 1000/μl.

    Participants without a post-baseline disease assessment were considered non-responders.


  • Overall Survival [ Time Frame: From first dose of blinatumomab until the data cut-off date; median observation time was 8.8 months. ]

    Overall survival was assessed from the date the participant received the first infusion of blinatumomab until death from any cause or the date of the last follow-up.

    Participants still alive at the data cut-off date were censored on the last documented visit date or the date of the last contact when the patient was last known to have been alive.


  • Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission [ Time Frame: Up to the data cut-of date of 20 May 2015; Maximum duration on study was 14.5 months. ]
    Participants who achieved remission (CR/CRh*) during the first 2 cycles of treatment and received an allogeneic HSCT.

  • 100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant [ Time Frame: From the date of allogeneic HSCT until the data cut-off date of 20 May 2015; median observation time was 3.2 months. ]

    The analysis of 100-day mortality after allogeneic HSCT was assessed for participants who received an allogeneic HSCT while in remission (CR/CRh*) after 2 cycles of blinatumomab treatment and did not receive any additional antileukemic treatment. 100-day mortality after allogeneic HSCT was calculated relative to the date of allogeneic HSCT.

    The 100-day mortality rate after allogeneic HSCT was defined as the percentage of participants having died up to 100 days after allogeneic HSCT estimated using the estimated time to death in percent calculated by Kaplan-Meier methods. Participants alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive.


  • Number of Participants With Adverse Events [ Time Frame: From the first dose of blinatumomab until 30 days after the last dose, up to the cut-off date of 20 May 2015; the median duration of treatment was 53.8 days. ]

    Adverse events (AEs) were graded for severity according to the CTCAE version 4.0, where Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.

    Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living.

    Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.

    Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE. Treatment-related adverse events (TRAEs) were those assessed by the investigator as possibly related to blinatumomab based on response to the question: Is there a reasonable possibility that the event may have been caused by blinatumomab or other protocol-specified therapies/procedures?


  • Number of Participants Who Developed Anti-blinatumomab Antibodies [ Time Frame: Day 29 of each treatment period and 30 days after the last dose ]
    Anti-blinatumomab binding antibodies were evaluated with a validated blinatumomab anti-drug antibody assay with the electrochemiluminescence detection technology.

  • Steady State Concentration of Blinatumomab [ Time Frame: Cycle 1, day 8, 6 to 8 hours after the dose step to 28 μg/day, and Cycle 2, day 1, 6 to 8 hours after blinatumomab infusion ]

Enrollment: 45
Actual Study Start Date: January 3, 2014
Study Completion Date: January 6, 2017
Primary Completion Date: May 20, 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Blinatumomab

Participants will receive blinatumomab by continuous intravenous (CIVI) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieve a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.

The initial dose will be 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 for all subsequent cycles of treatment.

Drug: Blinatumomab
Blinatumomab is administered as a continuous intravenous infusion (CIV). A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab followed by a 2-week treatment-free interval.
Other Names:
  • Blincyto®
  • AMG 103

Detailed Description:
This is a single-arm Simon II stage design, multicenter study consisting of a screening period, an induction treatment period (2 cycles of blinatumomab), a consolidation treatment period (up to 3 additional cycles of blinatumomab for applicable participants), and a safety follow-up visit 30 days after treatment. Following the safety follow-up visit, participants will be followed for response duration and survival every 3 months for 18 months or death, whichever occurs first.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Patients with Ph+ B-precursor ALL, with any of the following:

    • Relapsed or refractory to at least one second generation tyrosine kinase inhibitor (TKI) (dasatinib, nilotinib, bosutinib, ponatinib)
    • OR intolerant to second generation TKI and intolerant or refractory to imatinib mesylate
  • Greater than 5% blasts in bone marrow
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Age ≥ 18 years of age, at the time of informed consent.
  • Subject has provided informed consent or subject's legally acceptable representative has provided informed consent when the subject has any kind of condition that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent.

Exclusion Criteria

  • History of malignancy other than ALL within 5 years prior to start of protocol-required therapy, except for adequately treated selected cancers without evidence of disease
  • History or presence of clinically relevant central nervous system (CNS) pathology as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis
  • Active ALL in the CNS or testes
  • Isolated extramedullary disease
  • Current autoimmune disease or history of autoimmune disease with potential CNS involvement
  • Allogeneic hematopoietic stem cell transplantation (HSCT) within 12 weeks before blinatumomab treatment
  • Active acute or extensive chronic graft-versus-host disease (GvHD) which included the administration of immunosuppressive agents to prevent or treat GvHD within 2 weeks before blinatumomab treatment
  • immediately previous cancer chemotherapy, radiotherapy, or immunotherapy; and eligibility for allogeneic HSCT at the time of enrollment.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02000427


Locations
United States, California
Research Site
Duarte, California, United States, 91010
Research Site
La Jolla, California, United States, 92093-0960
United States, Georgia
Research Site
Atlanta, Georgia, United States, 30322
United States, Minnesota
Research Site
Rochester, Minnesota, United States, 55905
United States, Missouri
Research Site
Saint Louis, Missouri, United States, 63110
United States, New York
Research Site
New York, New York, United States, 10065
United States, North Carolina
Research Site
Durham, North Carolina, United States, 27710
United States, Texas
Research Site
Houston, Texas, United States, 77030
France
Research Site
Nantes Cedex 1, France, 44093
Research Site
Paris Cedex 10, France, 75475
Research Site
Toulouse cedex 9, France, 31059
Germany
Research Site
Berlin, Germany, 12200
Research Site
Essen, Germany, 45122
Research Site
Frankfurt am Main, Germany, 60590
Research Site
Würzburg, Germany, 97080
Italy
Research Site
Bergamo, Italy, 24127
Research Site
Bologna, Italy, 40138
Research Site
Roma, Italy, 00161
Research Site
Venezia, Italy, 30174
Research Site
Verona, Italy, 37134
United Kingdom
Research Site
London, United Kingdom, NW3 2PF
Research Site
Sutton, United Kingdom, SM2 5PT
Sponsors and Collaborators
Amgen
Investigators
Study Director: MD Amgen
  More Information

Additional Information:
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT02000427     History of Changes
Other Study ID Numbers: 20120216
2006-006520-19 ( EudraCT Number )
First Submitted: November 15, 2013
First Posted: December 4, 2013
Results First Submitted: July 12, 2017
Results First Posted: August 9, 2017
Last Update Posted: August 9, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Amgen:
Relapsed; Refractory; Philadelphia Positive; B-precursor; Acute Lymphoblastic Leukemia; ALL; Blinatumomab; Leukemia;

Additional relevant MeSH terms:
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Blinatumomab
Antibodies, Bispecific
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs